A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination with either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients with Advanced Malignancies
Cancer cells divide rapidly and need special proteins to repair their DNA as they reproduce. If their DNA is not repaired, the cancer cells may die. ATM is a protein that is important for DNA damage repair, and AZD0156 is a new drug that blocks ATM.
In this study, researchers are combining AZD0156 with other anticancer drugs in people with advanced cancers that have continued to grow despite standard therapies. The primary goal of this study is to determine whether combining AZD0156 with other anticancer drugs is safe in patients. Another goal is to obtain a preliminary idea of whether combining AZD0156 with other anticancer drugs can shrink tumors. AZD0156 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced cancer that has continued to grow despite standard therapies.
- At least 4 weeks must pass between completion of prior therapies and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for people age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Wassim Abida at 646-888-4226.